Special Issue "Leukaemia: Diagnosis and Treatment"
A special issue of Reports (ISSN 2571-841X).
Deadline for manuscript submissions: 30 June 2019
Dr. Geoffrey Brown
Institute of Clinical Sciences, Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
Website 1 | Website 2 | E-Mail
Interests: haematopoiesis; cell decision-making; cell differentiation; myeloid leukaemias; retinoids
Leukaemia is a neoplastic disease of the white blood cells. In the acute sub-types, cells proliferate and fail to mature normally; whilst in chronic types there is an excess of ineffective mature cells. Leukaemia has two peaks of incidence, first in childhood and the second in old age, and the disease is more common in males than in females. Today, the cure rate is relatively high for children and there has been substantial improvement since Sidney Farber introduced the first chemotherapy trials in the 1940s. Unfortunately and particularly for elderly people, the cure rates are still low for acute leukaemia, and they vary substantially between different types and subtypes of leukaemia. The introduction of Bcr-Abl kinase inhibitors has revolutionized the therapy for chronic myeloid leukaemia, whilst the use of all-trans-retinoic acid, to target PML-RARA fusion gene, led to a great improvement in the treatment of acute promyelocytic leukaemia. These advances exemplify the need to tailor treatments towards the mutation(s) that occurs in each particular subtype of leukaemia. In turn, detailed diagnosis of the genetic insult(s) is also important. This Special Issue of Reports is open for articles that provide insights into the underlying mutations, the diagnostic procedures, the biology of leukaemia, the nature of leukaemia stem cells, and old, new and repurposed therapies including for the treatment of disease relapse.
Prof. Dr. Ewa Marcinkowska
Dr. Geoffrey Brown
Prof. Dr. Ken Mills
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Reports is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) is waived for well-prepared manuscripts submitted to this issue. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- acute leukaemia
- chronic leukaemia
- myelodysplastic syndromes
- new therapy strategies
- gene aberrations
- leukaemia stem cells
- disease classification and diagnosis
- disease monitoring